ULURU Inc. announced unaudited consolidated financial results for the fourth quarter and year ended December 31, 2015. For the fourth quarter of 2015, the company reported a net loss of $366,212 or $0.01 per basic and diluted share, compared with a net profit of $318,028, or $0.01 per basic and diluted share, for the same period last year. Total revenues for the fourth quarter of 2015 were $357,295, as compared to $229,799 for the fourth quarter of 2014. The increase of approximately $127,000 in revenues from the fourth quarter of 2015 compared to the fourth quarter of 2014 was primarily due to an increase of $146,000 in licensing fees related to the company's international distributors. This increase in Revenue was partially offset by a decrease of $10,000 in royalties related to Altrazeal® from the company's international distributors and a decrease of $9,000 in Altrazeal® product sales by the company's international distributors. Operating loss was $292,145 against $811,987 a year ago. Loss before income taxes was $366,212 against income before income taxes of $318,028 a year ago.

For the year ended December 31, 2015, the company reported a net loss of $2,699,954 million, or $0.10 per basic and diluted share, compared with a net loss of $1,938,837, or $0.08 per basic and diluted share, for the same period of 2014. Total revenues were $935,739, as compared to $863,857 for the same period in 2014. The increase of approximately $72,000 in Revenue was due primarily to an increase of $149,000 in licensing fees related to the company's international distributors. This increase in Revenue was partially offset by a decrease of $51,000 in royalties related to Altrazeal® from the company's international distributors and a decrease of $26,000 in Altrazeal® product sales by the company's international distributors. Operating loss was $2,441,667 against $2,904,704 a year ago. Loss before income taxes was $2,699,954 against $1,938,837 a year ago.